Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835900 · ClinicalTrials.gov registry record · Phase 2
An Alternative Dosing Schedule of Varenicline for Smoking Cessation
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00835900 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 60 participants.
The verdict
NCT00835900, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.
Interventions
- DRUG placebo
- DRUG varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-03 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835900
The ClinicalTrials.gov registry entry for NCT00835900 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00835900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835900 about?
NCT00835900 is a clinical study titled "An Alternative Dosing Schedule of Varenicline for Smoking Cessation". The purpose of this study is to explore the use of an prolonged alternative dosing schedule using varenicline for smoking cessation leading to greater quit rates and higher rates of continuous abstinence.
What is the current status of trial NCT00835900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2009-03. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00835900?
The interventions under investigation include: placebo (DRUG), varenicline (DRUG).
Who is sponsoring clinical trial NCT00835900?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.